D13S25 Deletion LPH 043

Chromosomal abnormalities on chromosome 13q occur in 16 - 40% of multiple myeloma cases and are associated with poor prognosis. Deletions affecting the 13q14 band are also the most frequent genetic abnormalities of B-cell Chronic Lymphocytic Leukaemia (B-CLL). Two non-coding RNA genes, DLEU1 and DLEU2 and the genetic marker D13S319 span the pathogenic critical region 13q14.3. DLEU1 is considered to be the most likely CLL-associated candidate tumour suppressor gene within the 13q14 region. It has been postulated that a gene telomeric to the D13S319 marker encompassing D13S25 and 206XF12 may be important in cases where there are hemizygous deletions and that this gene is a putative tumour suppressor gene. The Cytocell D13S25 deletion probe covers the marker, the telomeric end of DLEU1 and the centromeric end of DLEU7.